SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- obesity/erectile dysfunction

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (381)1/17/2019 9:02:09 AM
From: scaram(o)uche  Read Replies (2) of 435
 
Well....... PRs of course often don't tell entire story, but second generation molecule is incredibly effective, second cohort of a phase II study. PR suggests no safety signal....

zafgen.gcs-web.com

Don't know if company has described difference between beloranib and 1061, described off target tox for beloranib. If it has, this is worth watching.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext